Losortan Potassium
Product Images NDC 53002-5643

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losortan Potassium (NDC 53002-5643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losapotatab1 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 01)

Chemical structure of Losartan Potassium showing the arrangement of atoms including chlorine, nitrogen, potassium ion, and hydrocarbon groups as part of the molecular configuration.*

FDA Label Image

Losapotatab2 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 02)

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol (dashed line) and Losartan Potassium (solid line). The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients. The graph includes a note on adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Losapotatab3 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 03)

A line graph comparing the percentage of patients experiencing fatal or non-fatal stroke over a study period of 66 months for Atenolol (dashed line) and Losartan Potassium (solid line). The x-axis represents study months, and the y-axis shows the percentage of patients. The graph indicates an adjusted risk reduction of 25% with a p-value of 0.001 for Losartan Potassium compared to Atenolol.*

FDA Label Image

Losapotatab (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 04)

A comparative hazard ratio forest plot chart showing primary composite and stroke (fatal/non-fatal) event rates between Losartan-K and Atenolol groups, segmented by patient subgroups including age, gender, race, ischemic heart status, diabetes, and cardiovascular history. The chart displays event rates, hazard ratios, and confidence intervals.*

FDA Label Image

Losapotatab5 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 05)

A line graph showing the percentage of patients with events over time (months) comparing Losartan Potassium Tablet and placebo. The solid line represents Losartan Potassium, and the dotted line represents placebo. The chart notes a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Label Image (Lbl530025643)

Losortan Potassium 50 mg tablets packaging label showing directions to take 1 tablet daily as directed. The label includes placeholders for patient and clinic information, prescription details, and barcode with NDC 53002-5643. The labeler is RPK Pharmaceuticals, Inc. The package size is 100 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.